Sivik Global Healthcare LLC Has $4.44 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Sivik Global Healthcare LLC lowered its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 28.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,000 shares of the company’s stock after selling 10,000 shares during the period. Johnson & Johnson accounts for 2.5% of Sivik Global Healthcare LLC’s holdings, making the stock its 18th largest holding. Sivik Global Healthcare LLC’s holdings in Johnson & Johnson were worth $4,438,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Taylor & Morgan Wealth Management LLC grew its holdings in shares of Johnson & Johnson by 1.6% during the second quarter. Taylor & Morgan Wealth Management LLC now owns 3,580 shares of the company’s stock valued at $635,000 after buying an additional 57 shares during the last quarter. Circle Wealth Management LLC grew its holdings in shares of Johnson & Johnson by 0.5% during the first quarter. Circle Wealth Management LLC now owns 11,326 shares of the company’s stock valued at $2,007,000 after buying an additional 59 shares during the last quarter. Red Wave Investments LLC grew its holdings in shares of Johnson & Johnson by 2.0% during the second quarter. Red Wave Investments LLC now owns 2,986 shares of the company’s stock valued at $530,000 after buying an additional 59 shares during the last quarter. Argus Investors Counsel Inc. grew its holdings in shares of Johnson & Johnson by 0.6% during the second quarter. Argus Investors Counsel Inc. now owns 10,936 shares of the company’s stock valued at $1,941,000 after buying an additional 61 shares during the last quarter. Finally, Alta Capital Management LLC grew its holdings in shares of Johnson & Johnson by 0.4% during the second quarter. Alta Capital Management LLC now owns 15,824 shares of the company’s stock valued at $2,808,000 after buying an additional 61 shares during the last quarter. Institutional investors and hedge funds own 68.59% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on JNJ. Atlantic Securities reduced their price objective on shares of Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a report on Wednesday, October 19th. Barclays assumed coverage on shares of Johnson & Johnson in a report on Monday, October 17th. They set an “equal weight” rating and a $175.00 price objective for the company. Morgan Stanley cut their price target on shares of Johnson & Johnson from $174.00 to $170.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 19th. Bank of America cut their price target on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a report on Friday, October 14th. Finally, Sanford C. Bernstein cut their price target on shares of Johnson & Johnson from $194.00 to $190.00 in a report on Wednesday, October 19th. Seven analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $181.33.

Insider Activity

In other news, insider William Hait sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, October 24th. The shares were sold at an average price of $171.55, for a total value of $2,573,250.00. Following the sale, the insider now owns 80,236 shares of the company’s stock, valued at $13,764,485.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, EVP Kathryn E. Wengel sold 16,410 shares of the business’s stock in a transaction that occurred on Wednesday, November 9th. The shares were sold at an average price of $173.42, for a total value of $2,845,822.20. Following the sale, the executive vice president now owns 71,311 shares of the company’s stock, valued at $12,366,753.62. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider William Hait sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, October 24th. The shares were sold at an average price of $171.55, for a total transaction of $2,573,250.00. Following the transaction, the insider now directly owns 80,236 shares of the company’s stock, valued at approximately $13,764,485.80. The disclosure for this sale can be found here. Insiders have sold a total of 118,795 shares of company stock valued at $20,230,174 over the last quarter. Company insiders own 0.35% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $176.20 on Monday. The firm has a market cap of $460.67 billion, a price-to-earnings ratio of 24.54, a P/E/G ratio of 3.49 and a beta of 0.57. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69. The firm’s 50-day simple moving average is $167.84 and its two-hundred day simple moving average is $171.29.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its quarterly earnings data on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, topping the consensus estimate of $2.49 by $0.06. The business had revenue of $23.79 billion for the quarter, compared to analyst estimates of $23.44 billion. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The company’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.60 earnings per share. As a group, equities analysts forecast that Johnson & Johnson will post 10.04 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 6th. Stockholders of record on Tuesday, November 22nd will be given a $1.13 dividend. This represents a $4.52 annualized dividend and a dividend yield of 2.57%. The ex-dividend date is Monday, November 21st. Johnson & Johnson’s dividend payout ratio (DPR) is currently 62.95%.

Johnson & Johnson declared that its Board of Directors has approved a stock repurchase plan on Wednesday, September 14th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the company to reacquire up to 1.2% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s management believes its shares are undervalued.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.